ReviewCurrent pharmaceutical design2009

Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Rodrigo Machado-Vieira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.